# Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus

Study · id `cardio:ct-nct07552389` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07552389](<https://clinicaltrials.gov/study/NCT07552389>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07552389

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 228 participants.

## Technical summary

Registry record NCT07552389. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-18 (actual); primary completion 2028-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 228 participants (planned count; ClinicalTrials.gov record NCT07552389, source copy `cardio:ctgov-nct07552389-2026-04-27`, retrieved 2026-10-26)
- Started: 2025-12-18 (actual) (ClinicalTrials.gov record NCT07552389, source copy `cardio:ctgov-nct07552389-2026-04-27`, retrieved 2026-10-26)
- Primary completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07552389, source copy `cardio:ctgov-nct07552389-2026-04-27`, retrieved 2026-10-26)
- Completion: 2028-12 (anticipated) (ClinicalTrials.gov record NCT07552389, source copy `cardio:ctgov-nct07552389-2026-04-27`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07552389, source copy `cardio:ctgov-nct07552389-2026-04-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07552389-2026-04-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
- Condition: Hypertension
- Condition: Diabete Type 2
- Intervention (Drug): Test group
- Intervention (Drug): Exploratory test group
- Intervention (Drug): Control group 1
- Intervention (Drug): Control group 2
- Lead sponsor: Hanlim Pharm. Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Hanlim Pharm. Co., Ltd. (`cardio:org-hanlim-pharm-co-ltd`)

## Provenance

Content hash: 424a995397d59353de0aff1a0bdeeb8208937fbdaf4ba3ad52a53a883f3e4ccd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
